Exosomal Delivery of AntagomiRs Targeting Viral and Cellular MicroRNAs Synergistically Inhibits Cancer Angiogenesis.

antiangiogenesis exosome miRNA nasopharyngeal carcinoma

Journal

Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621

Informations de publication

Date de publication:
19 Aug 2020
Historique:
received: 14 04 2020
revised: 01 07 2020
accepted: 14 08 2020
entrez: 14 9 2020
pubmed: 15 9 2020
medline: 15 9 2020
Statut: aheadofprint

Résumé

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated cancer characterized by a high degree of recurrence, angiogenesis, and metastasis. The importance of alternative pro-angiogenesis pathways including viral factors has emerged after decades of directly targeting various signaling components. Using NPC as a model, we identified an essential oncogenic pathway underlying angiogenesis regulation that involves the inhibition of a tumor suppressor, Spry3, and its downstream targets by EBV-miR-BART10-5p (BART10-5p) and hsa-miR-18a (miR-18a). Overexpression of EBV-miR-BART10-5p and hsa-miR-18a strongly promotes angiogenesis in vitro and in vivo by regulating the expression of VEGF and HIF1-α in a Spry3-dependent manner. In vitro or in vivo treatment with iRGD-tagged exosomes containing antagomiR-BART10-5p and antagomiR-18a preferentially suppressed the angiogenesis and growth of NPC. Our findings first highlight the role of EBV-miR-BART10-5p and oncogenic hsa-miR-18a in NPC angiogenesis and also shed new insights into the clinical intervention and therapeutic strategies for nasopharyngeal carcinoma and other virus-associated tumors.

Identifiants

DOI: 10.1016/j.omtn.2020.08.017 PMID: 32927364 PMC: PMC7494942
pubmed: 32927364
pii: S2162-2531(20)30246-8
doi: 10.1016/j.omtn.2020.08.017
pmc: PMC7494942
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

153-165

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Références

Mol Cancer. 2018 Feb 07;17(1):22
pubmed: 29415727
Nat Rev Microbiol. 2018 Nov;16(11):684-698
pubmed: 30143749
Cell. 1999 Mar 5;96(5):655-65
pubmed: 10089881
Int J Clin Exp Med. 2014 Apr 15;7(4):847-55
pubmed: 24955153
Oral Oncol. 2011 Jun;47(6):459-66
pubmed: 21530364
J Clin Invest. 2016 Apr 1;126(4):1208-15
pubmed: 27035812
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
J Biol Chem. 2001 Sep 28;276(39):36804-8
pubmed: 11495895
J Biol Chem. 2006 Oct 6;281(40):29993-30000
pubmed: 16893902
Oncogene. 2011 Feb 17;30(7):806-21
pubmed: 20956944
Cancer Sci. 2018 Feb;109(2):272-278
pubmed: 29247573
Cell Death Differ. 2013 Dec;20(12):1603-14
pubmed: 24212931
Oncogene. 2015 Apr 23;34(17):2156-66
pubmed: 25347742
Med Res Rev. 2017 Nov;37(6):1231-1274
pubmed: 28643862
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mol Biol Cell. 2004 May;15(5):2176-88
pubmed: 15004239
Trends Cell Biol. 2006 Jan;16(1):45-54
pubmed: 16337795
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
J Pathol. 2015 Jan;235(2):323-33
pubmed: 25251730
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9
pubmed: 17911266
Nat Biotechnol. 2011 Apr;29(4):341-5
pubmed: 21423189
Acta Biomater. 2019 Mar 1;86:1-14
pubmed: 30597259
Carcinogenesis. 2013 Feb;34(2):415-25
pubmed: 23097559
PLoS Pathog. 2014 Feb 27;10(2):e1003974
pubmed: 24586173
Cell. 2019 Apr 4;177(2):428-445.e18
pubmed: 30951670
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
Int J Mol Sci. 2017 Dec 23;19(1):
pubmed: 29295534
Nat Rev Mol Cell Biol. 2001 Apr;2(4):257-67
pubmed: 11283723
Anticancer Res. 2012 Aug;32(8):3201-10
pubmed: 22843893
Neoplasia. 2009 Nov;11(11):1174-84
pubmed: 19881953
Mol Ther. 2018 Feb 7;26(2):568-581
pubmed: 29292163
Neoplasia. 2013 Mar;15(3):231-8
pubmed: 23479502
J Virol. 2014 Dec;88(24):14301-9
pubmed: 25275137
PLoS Pathog. 2018 Dec 17;14(12):e1007484
pubmed: 30557400
Oncotarget. 2015 Dec 8;6(39):41766-82
pubmed: 26497204
Cell. 1998 Jan 23;92(2):253-63
pubmed: 9458049
Nat Commun. 2015 Jul 02;6:7353
pubmed: 26135619
Nat Immunol. 2010 Sep;11(9):806-13
pubmed: 20694010
Biomaterials. 2014 Feb;35(7):2383-90
pubmed: 24345736
Development. 1999 Jun;126(11):2515-25
pubmed: 10226010
Nat Commun. 2018 Nov 27;9(1):5009
pubmed: 30479336
Ther Adv Med Oncol. 2014 Nov;6(6):280-92
pubmed: 25364393
Clin Cancer Res. 2012 Mar 1;18(5):1404-14
pubmed: 22253412
Curr Cancer Drug Targets. 2018;18(3):266-277
pubmed: 28669338
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):
pubmed: 29158316
Cell Host Microbe. 2009 Apr 23;5(4):376-85
pubmed: 19380116

Auteurs

Jianguo Wang (J)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China; Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.

Qiang Jiang (Q)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Oluwasijibomi Damola Faleti (OD)

Departmrent of Laboratory Medicine, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.

Chi-Man Tsang (CM)

School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China; Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China.

Min Zhao (M)

PANACRO (Hefei) Pharmaceutical Technology Co., Ltd., Hefei, China.

Gongfa Wu (G)

Department of Pathology, Zengcheng District People's Hospital of Guangzhou City, Guangzhou, China.

Sai-Wah Tsao (SW)

School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.

Minyi Fu (M)

Otolaryngology-Head and Neck Surgery Department, Zhongshan City People's Hospital, Zhongshan, China.

Yuxiang Chen (Y)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Tengteng Ding (T)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Tuotuo Chong (T)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Yufei Long (Y)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Xu Yang (X)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Yuanbin Zhang (Y)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Yunxi Cai (Y)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Hanzhao Li (H)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Manli Peng (M)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Xiaoming Lyu (X)

Departmrent of Laboratory Medicine, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China. Electronic address: xiaomlyu@smu.edu.cn.

Xin Li (X)

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China. Electronic address: xinli268@gmail.com.

Classifications MeSH